Source: India.com

New Delhi: Two days after the World Health Organisation (WHO) put a pause on clinical trials of hydroxychloroquine (HCQ) for COVID-19, the Council of Scientific and Industrial Research (CSIR) said that India will continue the use of the anti-malarial drug.

“I’m sure WHO will take considered call in coming time. We should trust ICMR’s judgement, they are well qualified. Hence, we should continue.”

CSIR DG Shekhar Mande

Read the original article here: https://www.india.com/news/india/india-should-continue-use-of-hydroxychloroquine

Nigeria: NAFDAC To Continue Hydroxychloroquine Trial Despite WHO’s Directive

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Dr. Harvey Risch: Hydroxychloroquine, Ivermectin, and Other Therapeutics Highly Effective in Early COVID Treatment

I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.

Read More »

A Judge Stands up to a Hospital: “Step Aside” and Give a Dying Man Ivermectin

The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”

Read More »